We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day. On the other hand, the Dow registered a gain of 1.42%, and the technology-centric Nasdaq increased by 2.28%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had lost 2.61% over the past month. This has lagged the Medical sector's loss of 1.17% and was narrower than the S&P 500's loss of 5.73% in that time.
The investment community will be paying close attention to the earnings performance of Gilead Sciences in its upcoming release. The company is expected to report EPS of $1.73, up 231.06% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $6.78 billion, up 1.36% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $7.87 per share and revenue of $28.55 billion. These totals would mark changes of +70.35% and -0.7%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 0.05% rise in the Zacks Consensus EPS estimate. Gilead Sciences is currently a Zacks Rank #2 (Buy).
From a valuation perspective, Gilead Sciences is currently exchanging hands at a Forward P/E ratio of 13.61. Its industry sports an average Forward P/E of 18.52, so one might conclude that Gilead Sciences is trading at a discount comparatively.
It's also important to note that GILD currently trades at a PEG ratio of 0.7. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.51 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day. On the other hand, the Dow registered a gain of 1.42%, and the technology-centric Nasdaq increased by 2.28%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had lost 2.61% over the past month. This has lagged the Medical sector's loss of 1.17% and was narrower than the S&P 500's loss of 5.73% in that time.
The investment community will be paying close attention to the earnings performance of Gilead Sciences in its upcoming release. The company is expected to report EPS of $1.73, up 231.06% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $6.78 billion, up 1.36% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $7.87 per share and revenue of $28.55 billion. These totals would mark changes of +70.35% and -0.7%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 0.05% rise in the Zacks Consensus EPS estimate. Gilead Sciences is currently a Zacks Rank #2 (Buy).
From a valuation perspective, Gilead Sciences is currently exchanging hands at a Forward P/E ratio of 13.61. Its industry sports an average Forward P/E of 18.52, so one might conclude that Gilead Sciences is trading at a discount comparatively.
It's also important to note that GILD currently trades at a PEG ratio of 0.7. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.51 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.